Nkarta, Inc. (NASDAQ:NKTX) Shares Sold by Bridgeway Capital Management LLC

Bridgeway Capital Management LLC lowered its position in Nkarta, Inc. (NASDAQ:NKTX - Free Report) by 88.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 20,000 shares of the company's stock after selling 149,467 shares during the quarter. Bridgeway Capital Management LLC's holdings in Nkarta were worth $50,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the company. Wells Fargo & Company MN grew its holdings in shares of Nkarta by 27.8% in the fourth quarter. Wells Fargo & Company MN now owns 31,056 shares of the company's stock valued at $77,000 after purchasing an additional 6,763 shares during the period. Catalina Capital Group LLC boosted its stake in Nkarta by 57.5% during the fourth quarter. Catalina Capital Group LLC now owns 18,818 shares of the company's stock worth $47,000 after buying an additional 6,867 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in Nkarta by 41.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 23,958 shares of the company's stock worth $60,000 after buying an additional 7,030 shares during the period. American Century Companies Inc. boosted its stake in Nkarta by 8.8% during the fourth quarter. American Century Companies Inc. now owns 90,952 shares of the company's stock worth $226,000 after buying an additional 7,378 shares during the period. Finally, Wellington Management Group LLP boosted its stake in Nkarta by 4.1% during the fourth quarter. Wellington Management Group LLP now owns 225,224 shares of the company's stock worth $561,000 after buying an additional 8,883 shares during the period. Hedge funds and other institutional investors own 80.54% of the company's stock.

Nkarta Price Performance

Shares of NASDAQ NKTX traded down $0.04 during midday trading on Monday, hitting $1.70. The company's stock had a trading volume of 566,240 shares, compared to its average volume of 1,066,209. The business's fifty day simple moving average is $1.79 and its two-hundred day simple moving average is $2.18. Nkarta, Inc. has a 1 year low of $1.31 and a 1 year high of $8.23. The firm has a market capitalization of $120.63 million, a price-to-earnings ratio of -0.90 and a beta of 0.81.

Nkarta (NASDAQ:NKTX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.01. Analysts anticipate that Nkarta, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Stifel Nicolaus lowered their target price on shares of Nkarta from $15.00 to $14.00 and set a "buy" rating for the company in a research note on Thursday, March 27th. William Blair reaffirmed a "market perform" rating on shares of Nkarta in a research note on Thursday. HC Wainwright reaffirmed a "buy" rating and set a $18.00 target price on shares of Nkarta in a research note on Thursday, March 27th. Finally, Needham & Company LLC lowered their target price on shares of Nkarta from $11.00 to $10.00 and set a "buy" rating for the company in a research note on Thursday. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $14.67.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.